|
gptkbp:instance_of
|
gptkb:biotechnology
|
|
gptkbp:accreditation
|
CLIA certified
|
|
gptkbp:acquisition
|
gptkb:Genomic_Health
|
|
gptkbp:acquisition_year
|
gptkb:2019
|
|
gptkbp:advances
|
cutting-edge research
|
|
gptkbp:annual_report
|
published yearly
|
|
gptkbp:approves
|
FDA approved
|
|
gptkbp:business_model
|
direct-to-consumer
|
|
gptkbp:ceo
|
gptkb:Kevin_Conroy
|
|
gptkbp:clinical_trial
|
multiple
ongoing studies
peer-reviewed studies
|
|
gptkbp:collaboration
|
pharmaceutical companies
|
|
gptkbp:collaborations
|
academic institutions
|
|
gptkbp:community_involvement
|
health initiatives
|
|
gptkbp:community_outreach
|
health education initiatives
|
|
gptkbp:conflict
|
competition in diagnostics
|
|
gptkbp:customer_base
|
healthcare providers
|
|
gptkbp:economic_development
|
strategic acquisitions
|
|
gptkbp:employees
|
over 1,000
|
|
gptkbp:financial_performance
|
growing revenue
|
|
gptkbp:financial_support
|
resources available
|
|
gptkbp:focus
|
cancer screening
|
|
gptkbp:founded
|
gptkb:1995
|
|
gptkbp:founder
|
gptkb:Kevin_Conroy
|
|
gptkbp:future_goals
|
expanding product offerings
|
|
gptkbp:future_prospects
|
positive growth potential
|
|
gptkbp:headquarters
|
gptkb:Madison,_Wisconsin
|
|
gptkbp:healthcare
|
transforming diagnostics
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Exact Sciences
|
|
gptkbp:innovation
|
diagnostic solutions
|
|
gptkbp:investment
|
research and development
transparent communication
|
|
gptkbp:involved_technology
|
digital health solutions
|
|
gptkbp:is_a_platform_for
|
proprietary technology
|
|
gptkbp:leadership
|
diverse team
|
|
gptkbp:market
|
gptkb:United_States
|
|
gptkbp:market_position
|
gptkb:North_America
|
|
gptkbp:marketing_strategy
|
gptkb:expansion
|
|
gptkbp:mission
|
early detection of cancer
|
|
gptkbp:notable_products
|
gptkb:Cologuard
|
|
gptkbp:partnership
|
gptkb:Mayo_Clinic
gptkb:Cleveland_Clinic
|
|
gptkbp:partnerships
|
collaborative research
|
|
gptkbp:patient_education
|
awareness programs
|
|
gptkbp:product_line
|
screening tests
|
|
gptkbp:provides_guidance_on
|
gptkb:National_Institutes_of_Health
evidence-based practices
|
|
gptkbp:publications
|
research findings
|
|
gptkbp:reach
|
international markets
|
|
gptkbp:regulatory_compliance
|
healthcare regulations
multiple certifications
|
|
gptkbp:research_focus
|
non-invasive tests
|
|
gptkbp:revenue
|
$1.1 billion (2020)
|
|
gptkbp:side_effect
|
improved outcomes
improving patient care
|
|
gptkbp:social_responsibility
|
ethical practices
|
|
gptkbp:stock_exchange
|
gptkb:NASDAQ
|
|
gptkbp:stock_symbol
|
EXAS
|
|
gptkbp:sustainability_efforts
|
environmental responsibility
|
|
gptkbp:target_market
|
adults aged 45 and older
|
|
gptkbp:technology
|
molecular diagnostics
|
|
gptkbp:training
|
professional development
|
|
gptkbp:type_of_care
|
feedback mechanisms
|
|
gptkbp:bfsParent
|
gptkb:Centro_Universitario_de_Ciencias_Exactas_e_Ingenierías
gptkb:Federal_University_of_Ouro_Preto
gptkb:Federal_University_of_Lavras
gptkb:University_of_Vale_do_Acaraú
|
|
gptkbp:bfsLayer
|
6
|